

UNITED STATES DISTRICT COURT  
WESTERN DISTRICT OF WASHINGTON  
AT SEATTLE

DAVID WAYNE THOMAS, II,

Plaintiff,

v.

C.R. BARD, INC. and BARD PERIPHERAL  
VASCULAR, INC.,

Defendants.

Case No. C19-1464RSM

ORDER DENYING MOTION FOR  
SUMMARY JUDGMENT

**I. INTRODUCTION**

This matter comes before the Court on Defendants C.R. Bard, Inc. and Bard Peripheral Vascular, Inc.’s Motion for Summary Judgment. In this product liability action, David W. Thomas, II seeks to recover for injuries he suffered after implantation of a Bard Meridian Inferior Vena Cava (“IVC”) Filter. Plaintiff Thomas has previously withdrawn his claims for negligence per se, breach of warranty, negligent and fraudulent misrepresentation, fraudulent concealment, consumer protection violations, and punitive damages. *See* Dkt. #36 at 1 n.1. Defendants move to dismiss the remaining two causes of action: Count II (Strict Products Liability... Failure to Warn) and Count III (Strict Products Liability - Design Defect). Dkt. #26. Plaintiff opposes. Dkt. #36. For the reasons stated below, the Court finds that Plaintiff has established a genuine dispute as to material facts precluding summary judgment dismissal of either claim.

## II. BACKGROUND

On April 19, 2014, Mr. Thomas went to urgent care after experiencing abdominal pain and diminished food intake and appetite. Dkt. #27-3 at GROMC\_MDR00136. Doctors identified a “significant abdominal mass – highly suspicious for lymphoma/cancer” near his liver as well as bilateral pulmonary emboli. *Id.* at GROMC\_MDR00139. Mr. Thomas was transferred to Providence St. Peter Hospital for additional medical attention. Dkt. #27-4. He was given an anticoagulant and his treating physicians observed that the abdominal mass had compressed his inferior vena cava (“IVC”), causing a significant clot to form. Dkt. #27-5. They consulted with an interventional radiologist regarding the possible placement of an IVC filter so that Mr. Thomas’s anticoagulation could be discontinued in order to pursue a biopsy. *Id.* at STPETEFM\_MDR00024.

After explaining the procedure, benefits, and risks of implantation of Defendants’ Meridian Filter and after obtaining informed written consent, Dr. Alireza Bozorgmanesh implanted the filter through Mr. Thomas’s right jugular vein on April 22, 2014. Dkt. #27-6 at STPETEFM\_MDR00114-16; Dkt. #27-7 at STPETEFM\_MDR00362-63. The procedure was completed without incident. Dr. Bozorgmanesh recommended that the filter be removed “as soon as patient’s retroperitoneal adenopathy improves with improved mass effect on the IVC.” *Id.* at THOMASHD\_STPETEFM\_MDR00116. Mr. Thomas was hospitalized until April 27 and received care for the cancer that was causing the abdominal swelling and related clotting. Dkt. #27-8, STPETEFM\_MDR000011-15. After discharge he was instructed on certain follow up medications and treatments.

While Mr. Thomas continued his cancer treatment, his doctor noted on May 28, 2014, that it was not yet clear that the risks of a venous thromboembolism (“VTE”)—or clotting in the

1 veins—had “resolved rapidly enough to permit removal.” Dkt. #27-9,  
2 STPETEFM\_MDR00716-19. In October 2015 Mr. Thomas contacted the radiology vascular  
3 department at Providence St. Peter Hospital regarding the feasibility of removing his filter. Dkt.  
4 #27-10 at STPETEFM\_MDR00756-57.

5 After a CT scan showed “the IVC filter to be in place... with evidence for two of the  
6 filter struts to have perforated the IVC and have upturned barbs,” on December 10, 2015,  
7 doctors attempted to remove Mr. Thomas’s filter via ultrasound guided access to his right  
8 internal jugular vein, but were unable to do so after utilizing several different techniques and  
9 after Mr. Thomas began to experience discomfort. Dkt. #27-12.

10 In early 2016, Mr. Thomas’s doctors again discussed retrieving the filter and decided  
11 that he should remain on anticoagulation and not have further attempts at removal unless his  
12 lung function improved to a condition that would allow him to undergo a retroperitoneal lymph  
13 node dissection, a procedure that removes lymph nodes from the abdomen. Dkt. #27-13 at  
14 VMMC\_MDR00665. Mr. Thomas has had follow up exams and calls with several hospitals  
15 including Providence St. Peter regarding the positioning of the filter. Dkt. #27-14 at  
16 STPETEFM\_MDR00838-839; Dkt. #27-15 at VMMC\_MDR00979-980. Mr. Thomas’s cancer  
17 is in remission. Dkt. #27-16 at MCHS\_MDR02491.

18 The parties agree that the Information For Use (“IFU”) pamphlet, presumably sent to the  
19 hospital where Plaintiff had the filter implanted, included warnings about filter “penetration,”  
20 “migration,” and “fracture.” See Dkt. #37-32 at 8. Mr. Thomas will present evidence that these  
21 warnings were inadequate and did not reflect all the risks known to Defendants, but such is not  
22 at issue in this Motion.

23 Plaintiff filed this action on January 17, 2017. Dkt. #1.

1 During discovery, Mr. Thomas served a Plaintiff Fact Sheet (“PFS”), and Bard similarly  
2 served a Defendant Fact Sheet (“DFS”). Mr. Thomas alleges in his Fact Sheet that he has  
3 “chest pain” and “other pain and suffering, mental anguish, physical disability, emotional  
4 distress, loss of use/enjoyment of his life, [and] other non-economic damages.” Dkt. #27-18 at  
5 15. Plaintiff also alleged that the filter legs perforated the wall of his IVC, and added that his  
6 symptoms related to the filter include IVC thrombosis, chest pains, and currently necessitates  
7 anti-coagulant use. *Id.* at 15–16. Mr. Thomas, Dr. Alireza Bozorgmanesh, and Plaintiff’s  
8 expert Dr. Robert Allen were all deposed in 2020. The parties did not seek to depose any other  
9 witnesses before the deadline to do so. Defendants disclosed the report of case-specific expert  
10 Dr. Jeffrey Kalish on January 1, 2021. Plaintiff did not pursue a deposition of Dr. Kalish.  
11

### 12 III. DISCUSSION

#### 13 A. Legal Standard for Summary Judgment

14 Summary judgment is appropriate where “the movant shows that there is no genuine  
15 dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed.  
16 R. Civ. P. 56(a); *Anderson v. Liberty Lobby, Inc.*, 477 U.S. 242, 247 (1986). Material facts are  
17 those which might affect the outcome of the suit under governing law. *Anderson*, 477 U.S. at  
18 248. In ruling on summary judgment, a court does not weigh evidence to determine the truth of  
19 the matter, but “only determine[s] whether there is a genuine issue for trial.” *Crane v. Conoco,*  
20 *Inc.*, 41 F.3d 547, 549 (9th Cir. 1994) (citing *Federal Deposit Ins. Corp. v. O’Melveny &*  
21 *Meyers*, 969 F.2d 744, 747 (9th Cir. 1992)).  
22

23 On a motion for summary judgment, the court views the evidence and draws inferences  
24 in the light most favorable to the non-moving party. *Anderson*, 477 U.S. at 255; *Sullivan v. U.S.*  
25 *Dep’t of the Navy*, 365 F.3d 827, 832 (9th Cir. 2004). The Court must draw all reasonable  
26  
27  
28

1 inferences in favor of the non-moving party. *See O'Melveny & Meyers*, 969 F.2d at 747, *rev'd*  
 2 *on other grounds*, 512 U.S. 79 (1994). However, the nonmoving party must make a "sufficient  
 3 showing on an essential element of her case with respect to which she has the burden of proof"  
 4 to survive summary judgment. *Celotex Corp. v. Catrett*, 477 U.S. 317, 323 (1986).

#### 5 **B. Failure to Warn Claim**

6  
 7 The only remaining claims are product liability failure to warn and defective design  
 8 claims. In Washington, these claims are governed by the Washington Product Liability Act,  
 9 RCW 7.72 *et seq.* RCW 7.72.030(1) provides that a manufacturer is "subject to liability to a  
 10 claimant if the claimant's harm was proximately caused by the negligence of the manufacturer  
 11 in that the product was . . . not reasonably safe because adequate warnings or instructions were  
 12 not provided." Warnings are inadequate:

14 if, at the time of manufacture, the likelihood that the product would  
 15 cause the claimant's harm or similar harms, and the seriousness of  
 16 those harms, rendered the warnings or instructions of the  
 17 manufacturer inadequate and the manufacturer could have  
 provided the warnings or instructions which the claimant alleges  
 would have been adequate.

18 RCW 7.72.030(1)(b).

19 Under the "learned intermediary" doctrine, a medical device manufacturer satisfies its  
 20 duty to warn of dangers involved in using its product if the manufacturer "gives adequate  
 21 warning to the physician who prescribes it." *Terhune v. A.H. Robins Co.*, 577 P.2d 975, 977  
 22 (Wash. 1978); *see also Adams v. Synthes Spine Co., LP.*, 298 F.3d 1114, 1117 (9th Cir. 2002)  
 23 (citing *Terhune* and explaining that, "[u]nder Washington law, the 'consumer' of a prescription-  
 24 only medical device such as this is the physician, not the patient").  
 25  
 26

27 Here, Defendants assert Mr. Thomas cannot demonstrate proximate cause because the  
 28 implanting physician, Dr. Bozorgmanesh, stated in deposition that he cannot be sure he read the

1 IFU for this filter before the procedure. *See* Dkt. #26 at 11. Defendants argue that “to be  
2 successful on a claim for failure to warn, a plaintiff must prove that an adequate warning would  
3 have caused the product to be treated differently and avoided the harm.” *Id.* at 10 (citing *Ayers*  
4 *By and Through Smith v. Johnson & Johnson Baby Products Co.*, 797 P.2d 527, 530 (Wash. Ct.  
5 App. 1990), *aff’d*, 818 P.2d 1337 (Wash. 1991)). Defendants “recognize[] that it appears Dr.  
6 Bozorgmanesh had read some version of some Bard IFU at some point prior to his deposition,  
7 but he was not certain as to when or even if he had read the entire document.” *Id.* at 12.  
8 Defendants maintain it is therefore “impossible to say what impact, if any, a different, increased  
9 warning would have had...” *Id.* Defendants make no further arguments for dismissal of this  
10 claim.  
11

12  
13 In Response, Mr. Thomas argues:

14 Whether or not he could remember reading the IFU immediately  
15 prior to performing Mr. Thomas’s implant surgery, Dr.  
16 Bozorgmanesh was familiar with the IFU for every IVC filter  
17 model he used on his patients, including the Meridian filter, and he  
18 testified that he was familiar with the “warnings” section of the  
19 Meridian IFU prior to placing Mr. Thomas with the Meridian filter.  
20 *See* Ex. 3, Bozorgmanesh Dep., at 53:15–24, 55:1–25. Dr.  
21 Bozorgmanesh further testified that different IVC filter models  
22 presented different levels of risks. *Id.* at 64:21–25.... Dr.  
23 Bozorgmanesh testified that he would expect that before the  
24 Meridian filter was placed on the market, Bard would have tested it  
25 for safety and efficacy, and that he was surprised to learn that no  
26 such clinical studies were conducted. [*Id.*] at 62:13–24. He further  
27 testified that the lack of clinical testing is something he needed to  
28 know before making a decision on whether to utilize the Meridian  
filter on patients, as it would have caused him to consider safer  
filter models made by Bard’s competitors. *Id.* at 63:1–12. The lack  
of clinical testing was something Dr. Bozorgmanesh would have  
considered discussing with patients like Mr. Thomas as part of the  
risk/benefit analysis of the filter. *Id.* at 63:14–18, 64:14–19.

Dkt. #36 at 15 – 16.

Causation is typically a question of fact for the jury. Viewing the deposition testimony of Dr. Bozorgmanesh in the light most favorable to the non-moving party, the Court cannot say as a matter of law that that an adequate warning would have not caused the product to be treated differently in a way that would have avoided this harm. In the key passage relied on by Defendants, Dr. Bozorgmanesh is asked if he recalled reading the Meridian IFU prior to implanting the filter in Mr. Thomas and responds “I can’t say that I did prior to his case, but I can tell you at one point or another I have read the IFUs.... Not every word in the IFUs, but in general I have read them for most everything I use.” Dkt. #27-19 at 53:18–24. Defense counsel then asks “so based on that, would it be complete speculation to conclude that you, in fact, read this specific IFU prior to the time of implant?” and the doctor responds “I think so.” *Id.* at 53:25–54:3. Defense counsel makes hay of this apparent admission, but the Court reminds the parties that Dr. Bozorgmanesh is not a lawyer and finds his “I think so” statement not particularly conclusive. Based just on the above, a jury could easily find that Dr. Bozorgmanesh read the IFU at issue and agree with Plaintiff’s counsel’s arguments above. Further questioning by counsel in front of a jury is necessary. There is clearly a genuine dispute of material fact related to causation, precluding summary judgment. Defendants make no other arguments for dismissal of this claim.

### **C. Design Defect Claim**

Defendants point to Comment k to the Restatement (Second) of Torts § 402A as a basis to escape liability on this claim:

There are some products which, in the present state of human knowledge, are quite incapable of being made safe for their intended and ordinary use. . . . The seller of such products, again with the qualification that they are properly prepared and marketed, and proper warning is given, where the situation calls for it, is not to be held to strict liability for unfortunate

1 consequences attending their use, merely because he has  
2 undertaken to supply the public with an apparently useful and  
3 desirable product, attended with a known but apparently  
4 reasonable risk.

5 Defendants argue that, in the absence of a manufacturing defect (improper preparation) or  
6 inadequate warnings (improper marketing or warnings), manufacturers of medical devices are  
7 not to be held liable for injuries attending the use of such products. Dkt. #26 at 13 (citing  
8 *Taylor v. Intuitive Surgical, Inc.*, 187 Wn.2d 743, 764, 389 P.3d 517, 527). However, as the  
9 Court has found that inadequate warnings remain an issue for the jury, the Court cannot  
10 conclude as a matter of law that comment k precludes a design defect claim.

#### 11 IV. CONCLUSION

12 Having reviewed the relevant briefing and the remainder of the record, the Court hereby  
13 finds and ORDERS that Defendants' Motion for Summary Judgment, Dkt. #26, is DENIED.

14 DATED this 15<sup>th</sup> day of November, 2021.

15  
16  
17 

18 RICARDO S. MARTINEZ  
19 CHIEF UNITED STATES DISTRICT JUDGE  
20  
21  
22  
23  
24  
25  
26  
27  
28